Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada

Table 2

Base-case analysis results: incremental cost and incremental effect.

	Aerobika® device	No PEP/OPEP therapy
Total direct medical cost	$8,141.56	$8,835.71
Total QALYs	0.57	0.53
Incremental cost	−$694.15
Incremental effect (QALY gained)	0.04
Incremental cost-effectiveness ratio (ICER)	Aerobika® device is the dominant strategy

For variations, please see sensitivity analyses.